FDA Approves Isatuximab/VRd in Transplant-Ineligible NDMM
WEB5 days ago — Transplant-ineligible patients 80 years or younger with NDMM in the prospective, open-label study across 102 sites and 21 countries were randomly assigned 3:2 to receive isa-VRd or VRd alone. ... and dexamethasone for newly diagnosed multiple myeloma. FDA. News release. September 20, 2024. Accessed September 20, 2024. https://shorturl.at/B8d3c;
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone …
WEBDec 12, 2023 — Daratumumab has been approved for use in combination with various regimens for the treatment of patients with newly diagnosed multiple myeloma, including a regimen for those who are eligible for...
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed …
WEB2 days ago — The approval is supported by data from the randomized, open-label, phase 3 IMROZ study (ClinicalTrials.gov Identifier: NCT03319667), which included 446 patients with NDMM not eligible for stem ...
Newly diagnosed multiple myeloma: making sense of the menu
WEBDec 9, 2022 — This article reviews the current treatment options and strategies for patients with newly diagnosed multiple myeloma (NDMM) in 2022. It covers the definition, diagnosis, risk stratification, and induction therapy of …
ASH 2023: Advances in Combination Therapy for Newly …
WEBPhase 3 results of the IsKia trial showed the benefits of adding isatuximab to carfilzomib-lenalidomide-dexamethasone (KRd) induction and consolidation in terms of measurable residual disease (MRD)...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB2 days ago — Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not ...
Daratumumab-based quadruplet therapy for transplant-eligible …
WEBApr 22, 2024 — In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM).
Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM…
WEBNov 2, 2023 — Here, we present the results of NDMM pts for the first 4 years of inclusion (2017 to 2020). Pts with NDMM who receive front-line therapy with an autologous stem cell transplant (ASCT group) are described separately …
Daratumumab plus RVd for newly diagnosed multiple myeloma: final ...
WEBPatients with NDMM eligible for high-dose therapy (HDT) and autologous stem cell transplant (ASCT) were enrolled. Complete eligibility criteria have been published. 13 …
Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for ...
WEBTargeted Oncology: What led to the development of quadruplet therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM)? LAAHN HO FOSTER, …
Skip to content